Melinta Therapeutics (MLNTQ) Stock Price, News & Analysis

Company Overview

Melinta Therapeutics is a pharmaceutical company focused on the development and commercialization of antibiotics for serious and life-threatening bacterial infections. Its products have primarily targeted hospital and acute-care settings, as well as certain community-acquired infections, with an emphasis on treating drug-resistant pathogens and addressing unmet needs in infectious disease.

Melinta’s commercial portfolio has included Vabomere (meropenem and vaborbactam), an intravenous antibiotic used for certain serious infections caused by resistant bacteria; Orbactiv (oritavancin), a long-acting treatment for acute bacterial skin and skin-structure infections; Minocin for Injection (minocycline); and Baxdela (delafloxacin), an antibiotic approved for specified acute bacterial skin infections and community-acquired bacterial pneumonia.

The company was founded as Rib-X Pharmaceuticals and adopted the Melinta Therapeutics name in 2013. It later underwent financial restructuring, including a Chapter 11 bankruptcy process, and continued operating as a privately held specialty pharmaceutical business. Its products and commercial activities have primarily served healthcare providers and patients in the United States, with a focus on infectious-disease treatment.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.11 to $0.11
• 52-Week Range: $0.06 to $8.60
• Volume: 32,900 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MLNTQ
• CIK: N/A
• Web: www.cempra.com
• Phone: 908-617-1309
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A